No Data
Ningbo Tianyi Medical Appliance Co., Ltd. (SZSE:301097) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Abterra^ Medical (301097.SZ): Cumulatively repurchased 2.42% of shares
Abterra^ Medical (301097.SZ) announced that as of October 31, 2024, the company has repurchased a total of 1,427,400 shares of the company through the Shenzhen Stock Exchange stock trading system by means of centralized bidding trading, accounting for 2.42% of the company's current total share capital. The highest fill price was 42.80 yuan/share, the lowest fill price was 32.71 yuan/share, and the total fill amount was RMB 57,641,335.95 (excluding stamp duty, transaction commissions and other trading expenses). This repurchase is in compliance with relevant laws and regulations as well as the company's established repurchase plan.
Abterra^ medical (301097.SZ) signed a distribution contract with PMG, with the first year contract amount estimated to be 40 million US dollars.
格隆汇November 4th | abterra^ Medical (301097.SZ) announced that on October 31, 2024, the company signed a "DISTRIBUTION AGREEMENT" with ProCure Medical GmbH (hereinafter referred to as "PMG" or "Buyer"). According to the contract, the contract symbol is blood dialysis tubing, with a duration of 5 years, and the estimated amount for the first year of the contract is 40 million US dollars. Due to fluctuations in raw material prices each year, the two parties may agree to modify the conditions upon mutual agreement.
Tianyi Healthcare: Report for the third quarter of 2024
Abterra^ Medical (301097.SZ) released the performance for the first three quarters, with a net income of 6.3426 million yuan, a year-on-year decline of 89.61%.
Abterra^ Medical (301097.SZ) released the third quarter report for 2024, with revenue of 3....
Is Ningbo Tianyi Medical Appliance Co., Ltd.'s (SZSE:301097) Stock Price Struggling As A Result Of Its Mixed Financials?
Should Weakness in Ningbo Tianyi Medical Appliance Co., Ltd.'s (SZSE:301097) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?No Data
No Data
